ASPIRE Cristalle DBT System Receives Health Canada Medical Device License

By News Release

FUJIFILM Canada has received Health Canada medical device license for its ASPIRE Cristalle digital mammography solution. The company also has expanded its partnership with Christie Innomed to offer the product with superior service in every province across the country. ASPIRE Cristalle is featured with Digital Breast Tomosynthesis (DBT) technology, also known as 3D mammography, which can help radiologists better visualize lesions that can be obscured between varying layers of breast tissue.

“As a company that is steadfast in empowering clinicians to detect breast cancer at its earliest stage, we are proud to offer Fujifilm’s ASPIRE Cristalle mammography system to providers in the Canadian market with our long-term partner, Christie Innomed,” said Hideaki Tsuda, President for FUJIFILM Canada, Inc. “The best method to detect breast cancer early is through annual mammograms, and an imaging facility having the right technology in place to detect potential cancerous tumors is critical for the patient. FUJIFILM Canada looks forward to expanding our relationships with hospitals and clinics to provide them with the women’s health solutions that will help increase patient comfort and advance breast health care in the community.”

The ASPIRE Cristalle with DBT combines Fujifilm’s Hexagonal Close Pattern (HCP) capture technology and intelligent image processing to optimize dose and contrast based on individual breast composition. The result is low dose and fast acquisition of high-quality images for all breast types. In addition, patients can experience a noticeable improvement in comfort during procedures with Fujifilm’s patented, flexible comfort paddle design, which provides gentle and even compression that is designed to adapt to patient curves.

“The availability and accessibility of women's health services is a priority for the Canadian health system, and Christie Innomed has been committed to women’s health for the past 30 years. We are proud and excited to launch this revolutionary mammography system, with our long-term partner Fujifilm. It will undoubtedly make a positive impact on our customers, Canadian radiologists, and technologists.  Our mission has always been the same – to assist healthcare institutions to deliver the best care possible for the Canadian citizen.”  Martin Roy, President and CEO, Christie Innomed.

Back To Top

ASPIRE Cristalle DBT System Receives Health Canada Medical Device License .  Appl Radiol. 

By News Release| October 19, 2021

About the Author

News Release

News Release



Copyright © Anderson Publishing 2021